Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted psychotherapy for treatment-refractory PTSD in Dutch military veterans
NL-OMON61289Phase 2Not yet recruiting
- Sponsor
- ARQ National Psychotrauma Centre
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of psilocybin in post-traumatic stress disorder (PTSD), sponsored by ARQ National Psychotrauma Centre. Primary endpoints: Screen failures and drop-out, Treatment acceptability and adherence and 6 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
psilocybin
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NL-OMON61289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61289.